全文获取类型
收费全文 | 161篇 |
免费 | 2篇 |
专业分类
财政金融 | 3篇 |
工业经济 | 3篇 |
计划管理 | 20篇 |
经济学 | 91篇 |
综合类 | 22篇 |
旅游经济 | 3篇 |
贸易经济 | 10篇 |
农业经济 | 3篇 |
经济概况 | 8篇 |
出版年
2023年 | 2篇 |
2021年 | 4篇 |
2020年 | 8篇 |
2019年 | 6篇 |
2018年 | 7篇 |
2017年 | 8篇 |
2016年 | 10篇 |
2015年 | 4篇 |
2014年 | 10篇 |
2013年 | 52篇 |
2012年 | 2篇 |
2011年 | 9篇 |
2010年 | 8篇 |
2009年 | 6篇 |
2008年 | 5篇 |
2007年 | 4篇 |
2006年 | 3篇 |
2005年 | 1篇 |
2003年 | 3篇 |
2002年 | 2篇 |
2001年 | 3篇 |
2000年 | 2篇 |
1999年 | 4篇 |
排序方式: 共有163条查询结果,搜索用时 0 毫秒
61.
离婚家庭是单亲家庭的一种表现形式.成长于离婚家庭中的青少年比在双亲家庭中长大的孩子更易在自我认同、人际交往、社会认知、资源获取的过程中陷入困境.家庭社会工作通过运用个案工作、小组工作、社区工作、社会政策、家庭治疗等方法对处于成长困境的离婚家庭青少年进行介入. 相似文献
62.
This paper explores the implications of the disability grant for household members' well-being and adults' success on ART (antiretroviral therapy). It uses case studies based on data from an in-depth qualitative study of 10 households in KwaZulu-Natal. Receipt of the disability grant ensured that the basic needs of the HIV-infected adult could be met by other household members, especially when the grant was received when the person first met the qualifying criteria and in conjunction with ART. Where treatment was effective, HIV-infected adults were able to make substantial contributions to the well-being of other members in addition to the financial support provided by the grant itself. Thus, early access to financial support in conjunction with commencing ART may lead to improved health outcomes and reduce poverty and vulnerability associated with illness in poor households. This synergistic relationship between social welfare and treatment may in turn contribute to greater cost-efficiency. 相似文献
63.
Sari Hopson Adrianne Casebeer Stephen Stemkowski Dana Drzayich Antol Zhuliang Tao Andrew Howe 《Journal of medical economics》2018,21(2):152-162
Background: The increase in hospital acquisition of community oncology clinics in the US has led to a shift in the site-of-care (SOC) for infusion therapy from the physician office (PO) to the hospital outpatient (HO) setting.Objective: To investigate differences by SOC in treatment patterns, quality, and cost among patients with cancer undergoing first-line infusion therapy.Research design and methods: This retrospective analysis identified adult patients from Humana medical claims who initiated infusion therapy from 2008–2012 for five common cancer types in which infusion therapy is likely, including early stage breast cancer; metastatic breast, lung, and colorectal cancers; and non-Hodgkin’s lymphoma or chronic lymphocytic leukemia. Differences by SOC in first-line treatment patterns and quality of care at end-of-life, defined as infusions or hospitalizations 30 days prior to death, were evaluated using Wilcoxon-Rank Sum and Chi-square tests where appropriate. Differences in cost by SOC were evaluated using risk-adjusted generalized linear models.Main outcome measures: Treatment patterns, quality of care at end of life, healthcare costs.Results: There were differences in duration of therapy and number of infusions for some therapy regimens by SOC, in which patients in the HO had shorter duration of therapy and fewer infusions. There were no differences in quality of care at end-of-life by SOC. Total healthcare costs were 15% higher among patients in HO ($55,965) compared with PO ($48,439), p?<?.0001.Limitations: Analyses was restricted to a claims-based population of cancer patients within a health plan.Conclusion: This study, in an older, predominantly Medicare Advantage oncology cohort, found differences by SOC in treatment patterns and cost, but not quality. Where differences were found, patients receiving care in the HO had shorter duration of therapy and fewer infusions for specific treatment regimens, but higher healthcare costs than those treated in a PO. 相似文献
64.
Vimalanand Prabhu Jason Foo Harblas Ahir Eric Sarpong 《Journal of medical economics》2017,20(8):840-849
Aims: An increase in the prevalence of antimicrobial resistance among gram-negative pathogens has been noted recently. A challenge in empiric treatment of complicated intra-abdominal infection (cIAI) is identifying initial appropriate antibiotic therapy, which is associated with reduced length of stay and mortality compared with inappropriate therapy. The objective of this study was to assess the cost-effectiveness of ceftolozane/tazobactam?+?metronidazole compared with piperacillin/tazobactam (commonly used in this indication) in the treatment of patients with cIAI in UK hospitals.Methods: A decision-analytic Monte Carlo simulation model was used to compare costs (antibiotic and hospitalization costs) and quality-adjusted life years (QALYs) of patients infected with gram-negative cIAI and treated empirically with either ceftolozane/tazobactam?+?metronidazole or piperacillin/tazobactam. Bacterial isolates were randomly drawn from the Program to Assess Ceftolozane/Tazobactam Susceptibility (PACTS) database, a surveillance database of non-duplicate bacterial isolates collected from patients in the UK infected with gram-negative pathogens. Susceptibility to initial empiric therapy was based on the measured susceptibilities reported in the PACTS database.Results: Ceftolozane/tazobactam?+?metronidazole was cost-effective when compared with piperacillin/tazobactam, with an incremental cost-effectiveness ratio (ICER) of £4,350/QALY and 0.36 hospitalization days/patient saved. Costs in the ceftolozane/tazobactam?+?metronidazole arm were £2,576/patient, compared with £2,168/patient in the piperacillin/tazobactam arm. The ceftolozane/tazobactam?+?metronidazole arm experienced a greater number of QALYs than the piperacillin/tazobactam arm (14.31/patient vs 14.21/patient, respectively). Ceftolozane/tazobactam?+?metronidazole remained cost-effective in one-way sensitivity and probabilistic sensitivity analyses.Conclusions: Economic models can help to identify the appropriate choice of empiric therapy for the treatment of cIAI. Results indicated that empiric use of ceftolozane/tazobactam?+?metronidazole is cost-effective vs piperacillin/tazobactam in UK patients with cIAI at risk of resistant infection. This will be valuable to commissioners and clinicians to aid decision-making on the targeting of resources for appropriate antibiotic therapy under the premise of antimicrobial stewardship. 相似文献
65.
66.
抗生素序贯治疗老年急性下呼吸道感染的成本-效果分析 总被引:1,自引:0,他引:1
采用前瞻性、随机对照临床干预研究设计和药物经济学中的最小成本分析法,对老年急性下呼吸道感染患者的两种治疗方案:静脉、口服序贯治疗组和连续静脉治疗组进行了临床疗效对比,同时对两组患者细菌清除率、静脉治疗时间、住院日等进行比较,对两组的抗菌药物医疗费用进行药物经济学评价.发现:两种疗法的临床疗效相同,患者细菌清除率、体温、血像、胸片恢复正常的时间相似,差异无显著性(P>0.05),但序贯组的静脉用药时间、平均住院日和抗菌药物费用明显低于对照组(P<0.05).从而得出结论:对老年急性下呼吸感染患者抗菌药物序贯治疗是安全而有效的,而且有更加合理的成本-效果比,由静脉治疗转换口服治疗的最佳时间约为7d. 相似文献
67.
《Journal of medical economics》2013,16(1):10-15
AbstractObjective:Joint pain and swelling during gout flares may lead to considerable morbidity and disability, having an impact on patient work productivity and social participation. The objective of this study was to assess how gout flares affect these activities in patients with chronic gout refractory to conventional therapy.Methods:A 1-year prospective observational study was conducted among patients with symptomatic disease in the United States in 2001. Inclusion criteria required patients (1) to be age 18 years or older, (2) to have documented, crystal-proven gout, (3) to have symptomatic gout, and (4) to be intolerant or unresponsive to conventional therapy, reflected by SUA?≥?6.0?mg/dL. Patients were evaluated every 2 months. At each visit, patients completed a gout diary, which included number of flares experienced, duration and severity of each flare, and whether the flare caused: (1) work loss, (2) missed appointments or social events, or (3) impairment of self-care activities. The Short-Form Health Survey (SF-36) was also completed each visit.Results:Analyses were restricted to those who completed the first 6 months of the study (n?=?81). Mean number of flares per patient per year was 8.8. Of the patients who were <65 years, 78% reported at least 1 work day lost due to a gout attack during the year. Mean annual work day loss for those <65 years was 25.1 days. A total of 545 of patients reported at least one flare per year that impaired social activities, with a mean of 17.1 social days lost and 52% reported at least one flare per year that compromised normal self-care activities, with a mean of 16.9 days impairment. Correlations between the diary reports and activity-related questions from the SF-36 were significantly positive.Limitations:The study is limited by small sample size, lack of reference group, and inability to explicitly collect employment information. Age under 65 years was used as a proxy for employment eligibility.Conclusion:Flares in patients with chronic gout refractory to conventional therapy significantly affect patient work productivity and social activities. 相似文献
68.
on behalf of the FARO Study Group 《Journal of medical economics》2013,16(6):1110-1117
AbstractBackground and objectives:Secondary hyperparathyroidism (SHPT) is a frequent complication of CKD with incidence, prevalence, and costs increasing worldwide. The objective of this analysis was to estimate therapy cost of SHPT in a sub-population of the FARO study.Materials and Methods:In the FARO study, an observational survey aimed to evaluate patterns of treatment in patients with SHPT who had undergone hemodialysis, pharmacological treatments and biochemical parameters evolution data were collected in four surveys. Patients maintaining the same treatment in all sessions were grouped by type of treatment and evaluated for costs from the Italian National Health Service perspective.Results:Four cohorts were identified: patients treated with oral (PO) calcitriol (n?=?182), intravenous (IV) calcitriol (n?=?34), IV paricalcitol (n?=?62), and IV paricalcitol?+?cinacalcet therapy (n?=?20); the cinacalcet monotherapy group was not analysed due to low number of patients (n?=?9). Parathyroid hormone (PTH) level at baseline and effectiveness of treatments in suppressing PTH level were assessed to test comparability among cohorts: calcitriol PO patients were significantly less severe than others (PTH level at baseline lower than 300?pg/ml; p?<?0.0001); calcitriol IV patients did not reach significant reduction in PTH level. Paricalcitol and paricalcitol?+?cinacalcet treatment groups results were comparable, while only the IV paricalcitol cohort’s PTH level, weekly dosage, and cost decreased significantly from the first to the fourth survey (p?=?0.020, p?=?0.012, and p?=?0.0124, respectively). Total costs per week of treatment (including calcium-based phosphate binder and sevelamer) were significantly lower in the paricalcitol vs paricalcitol?+?cinacalcet cohort (p?<?0.001). Major limitations of this study are related to the survey design: not controlled and lack of comparability between cohorts; however, reflective of true practice patterns.Conclusions:The IV Paricalcitol cohort had significantly lower treatment costs compared with patients treated with paricalcitol?+?calcimemtics (p?<?0.001), without a significant difference in terms of baseline severity and PTH control. 相似文献
69.
《Journal of medical economics》2013,16(5):844-861
AbstractObjective:To model the cost effectiveness of paliperidone palmitate (paliperidone long-acting injectable; PLAI), a new once-monthly long-acting antipsychotic therapy, compared with risperidone long-acting injectable (RLAI) and olanzapine pamoate (OLAI), in multi-episode patients (two or more relapses) with schizophrenia in Sweden.Methods:A Markov decision analytic model was developed to simulate the history of a cohort of multi-episode patients transitioning through different health states on a monthly basis over a 5-year time horizon from the perspective of the Swedish healthcare system. Therapeutic strategies consisted of starting treatment with RLAI (mean dose 37.5?mg every 2 weeks), PLAI (mean dose 75?mg equivalent (eq.) every month) or OLAI (150?mg every 2 weeks or 300?mg every 4 weeks). Probability of relapse, level of adherence, side-effects (extrapyramidal symptoms, tardive dyskinesia, weight gain and diabetes) and treatment discontinuation (switch) were derived from long-term observational data when feasible. Incremental cost-effectiveness outcomes, discounted at 3% annually, included cost per quality-adjusted life-year (QALY) and cost per relapse avoided (expressed in 2009 Swedish Krona SEK).Results:Relative to RLAI and OLAI, PLAI is economically dominant: more effective (additional QALYs, less relapses) and less costly treatment option over a 5-year time horizon. The results were robust when tested in sensitivity analysis.Limitations:The impact of once-monthly treatment on adherence levels is not yet known, and not all variables that could impact on real-world outcomes and costs were included in this model.Conclusion:PLAI was cost saving from a Swedish payer perspective compared with RLAI and OLAI in the long-term treatment of multi-episode (two or more relapses) schizophrenia patients. 相似文献
70.
目的观察云南白药胶囊联合山莨菪碱治疗支气管扩张咯血的止血效果。方法将支气管扩张咯血患者56例随机分为治疗组和对照组,治疗组29例采用云南白药胶囊联合山莨菪碱治疗;对照组27例采用云南白药胶囊治疗。结果治疗组止血总有效率为89.7%,对照组总有效率为66.7%,两组比较差异有显著性(P〈0.05)。结论云南白药胶囊联合山莨菪碱是治疗支气管扩张咯血确切有效的止血方法。 相似文献